SE0400968D0 - Aryl glycine ether derivatives and their use - Google Patents

Aryl glycine ether derivatives and their use

Info

Publication number
SE0400968D0
SE0400968D0 SE0400968A SE0400968A SE0400968D0 SE 0400968 D0 SE0400968 D0 SE 0400968D0 SE 0400968 A SE0400968 A SE 0400968A SE 0400968 A SE0400968 A SE 0400968A SE 0400968 D0 SE0400968 D0 SE 0400968D0
Authority
SE
Sweden
Prior art keywords
sup
compounds
ether derivatives
sub
aryl glycine
Prior art date
Application number
SE0400968A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Bernstein
Cathy Dantzman
William Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0400968A priority Critical patent/SE0400968D0/xx
Publication of SE0400968D0 publication Critical patent/SE0400968D0/xx
Priority to JP2007508299A priority patent/JP2007532636A/ja
Priority to EP05722313A priority patent/EP1740552A1/en
Priority to PCT/SE2005/000499 priority patent/WO2005100324A1/en
Priority to CNA2005800165802A priority patent/CN1956969A/zh
Priority to US10/599,824 priority patent/US7368448B2/en
Priority to US12/052,830 priority patent/US20080234282A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0400968A 2004-04-14 2004-04-14 Aryl glycine ether derivatives and their use SE0400968D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0400968A SE0400968D0 (sv) 2004-04-14 2004-04-14 Aryl glycine ether derivatives and their use
JP2007508299A JP2007532636A (ja) 2004-04-14 2005-04-06 Ｎｋ１アンタゴニスト及びセロトニン再取り込み阻害剤としての２−（アリールアルコキシ）−１−フェニルエチルアミン誘導体
EP05722313A EP1740552A1 (en) 2004-04-14 2005-04-06 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
PCT/SE2005/000499 WO2005100324A1 (en) 2004-04-14 2005-04-06 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
CNA2005800165802A CN1956969A (zh) 2004-04-14 2005-04-06 作为nk1拮抗剂和5－羟色胺再吸收抑制剂的2－(芳基烷氧基)－1－苯乙基胺衍生物
US10/599,824 US7368448B2 (en) 2004-04-14 2005-04-06 2-(arylalkoxy)-1-phenylethylamine derivatives as NK1 antagonist and serotonin reuptake inhibitors
US12/052,830 US20080234282A1 (en) 2004-04-14 2008-03-21 2-(Arylalkoxy)-1-Phenylethylamine Derivatives As NK1 Antagonist And Serotonin Reuptake Inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400968A SE0400968D0 (sv) 2004-04-14 2004-04-14 Aryl glycine ether derivatives and their use

Publications (1)

Publication Number Publication Date
SE0400968D0 true SE0400968D0 (sv) 2004-04-14

Family

ID=32294310

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400968A SE0400968D0 (sv) 2004-04-14 2004-04-14 Aryl glycine ether derivatives and their use

Country Status (6)

Country Link
US (2) US7368448B2 (https=)
EP (1) EP1740552A1 (https=)
JP (1) JP2007532636A (https=)
CN (1) CN1956969A (https=)
SE (1) SE0400968D0 (https=)
WO (1) WO2005100324A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460919A1 (fr) 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US5389686A (en) 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
US5245080A (en) 1989-02-20 1993-09-14 Jouveinal Sa (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use
US5266599A (en) 1989-02-20 1993-11-30 Jouveinal S.A. Use of (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine to increase gastric discharge in a subject
US5362756A (en) 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
GB9226581D0 (en) * 1992-12-21 1993-02-17 Merck Sharp & Dohme Therapeutic agents
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists

Also Published As

Publication number Publication date
WO2005100324A1 (en) 2005-10-27
US7368448B2 (en) 2008-05-06
EP1740552A1 (en) 2007-01-10
CN1956969A (zh) 2007-05-02
US20080234282A1 (en) 2008-09-25
JP2007532636A (ja) 2007-11-15
US20070185127A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
NZ593295A (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
MY130803A (en) New quinuclidine amide derivatives
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
DE602004021921D1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
MY148487A (en) Biphenyl derivatives
JP2009541443A5 (https=)
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0513713A (pt) derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
ATE364044T1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung